The city of New Orleans, Louisiana, currently has 3 active clinical trials seeking participants for Multiple Sclerosis research studies.
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Recruiting
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relations... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/24/2024
Locations: Ochsner Baptist Clinical Trials Unit (CTU) Site Number : 8400107, New Orleans, Louisiana
Conditions: Primary Progressive Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/22/2024
Locations: Ochsner Clinic Foundation ., New Orleans, Louisiana
Conditions: Relapsing Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
Recruiting
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study will also assess changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if... Read More
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
02/01/2024
Locations: Novartis Investigative Site, New Orleans, Louisiana
Conditions: Relapse Remitting Multiple Sclerosis